UCDCCC NCTN UG1 PROGRAM

UCDCCC NCTN UG1 项目

• 批准号: 9888340
• 负责人: DAVID R GANDARA
• 金额: $ 52.16万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-06 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9888340
• 关键词: Area; Awareness; Biometry; California; Cancer Control; Clinical Research; Clinical Trials; Communities; Comprehensive Cancer Center; Ensure; Faculty; Genomics; Goals; Health; Human; Laboratories; Lead; Leadership; Link; Malignant Neoplasms; Medical Oncology; Molecular Biology; NCI-Designated Cancer Center; Nursing Research; Pathology; Population; Radiation Oncology; Radiology Specialty; Research Personnel; Research Support; Resources; Rural Minority; Site; Structure; Surgical Specialties; Translational Research; Translations; base; biomedical referral center; cancer care; cancer prevention; career development; design; experience; improved; innovation; medical specialties; multidisciplinary; patient population; programs; rural underserved; tumor

PROJECT SUMMARY/ABSTRACT As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer care to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this application as a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD, UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the NCTN group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to NCI-sponsored clinical trials activities, as well as to NCI-related steering committees and initiatives. This UG1 effort is anticipated to increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. With an already strong track record in translational and clinical research leadership for NCTN, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for clinical trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials “hub” for accrual to NCI-sponsored studies throughout North-Central California, this NCTN UG1 initiative creates a additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will be impactful and ensure robust accrual to NCTN trials.

项目概要/摘要 作为唯一一家 NCI 指定为北加州内陆约 600 万人服务的癌症中心， 加州大学戴维斯分校综合癌症中心 (UCDCCC) 为大型和大型癌症中心提供初级癌症护理。 不断增长的人口，并作为该地区专科癌症护理的三级转诊中心。 申请作为 NCTN 网络领导学术参与网站，由医学博士 David R Gandara 领导 Richard K Valicenti 医学博士、UCDCCC 将利用已经建立的多学科癌症团队 来自医学肿瘤学、放射肿瘤学、外科专业、分子生物学/基因组学的研究人员， 病理学、放射学、生物统计学、护理和临床研究支持，提供临床试验专业知识， 在广泛的肿瘤类型和 NCTN 研究中的科学和行政领导力和收益 在整个 NCTN 集团网络中，其教师拥有长期且可靠的记录。 对 NCI 赞助的临床试验活动以及 NCI 相关指导委员会做出有影响力的贡献 UG1 的这项工作预计将扩大参与的范围和范围，包括 整合更多研究人员并为新教师和初级教师提供职业发展机会 NCTN 在转化和临床研究领导力方面已经拥有良好的记录， UCDCCC 准备利用独特的机构优势作为临床试验的实验室资源 并为假设驱动的临床研究做出贡献。 基于二十多年来作为 NCI 资助研究的临床试验“中心”的经验 在整个加州中北部，NCTN UG1 计划为 UCDCCC 创造了额外的机会 既增加了主站点的累积量，又通过 UCDCCC 将 NCTN 试验的访问范围扩展到社区 癌症护理网络和附属网站，其中包括大量服务不足的农村和少数民族患者 总之，UCDCCC 代表了一个跨学科的组织和领导结构。 与临床试验计划相关联，该计划将产生影响并确保 NCTN 试验的稳健增长。